E3XBio Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Investors
  • 1

E3XBio General Information

Description

Developers of inhibitors and activators of E3 Ubiquitin ligases intended to be used for drug discovery and development. The company's platform offers streamlined screening paradigm and direct cellular and animal model assays, enabling healthcare institutions to avail a simplified, pragmatic drug discovery approach to identify first-in-class small molecules specifically directed towards Ub E3 HECT ligases.

Contact Information

Website
Ownership Status
Privately Held (no backing)
Financing Status
Corporation
Primary Industry
Drug Discovery
Primary Office
  • San Francisco, CA
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

E3XBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Grant 01-Sep-2014 Completed Generating Revenue
To view E3XBio’s complete valuation and funding history, request access »

E3XBio Executive Team (4)

Name Title Board Seat Contact Info
Lori Rafield Ph.D Co-Founder & Chief Executive Officer
Paul Godowski Ph.D Co-Founder & Chief Scientific Officer
David Morgans Ph.D Co-Founder & Vice President, Drug Discovery
William Harte Ph.D Co-Founder & Vice President, Technology Platforms
To view E3XBio’s complete executive team members history, request access »

E3XBio Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Breakout Labs Not-For-Profit Venture Capital Minority 000 0000 000000 0
To view E3XBio’s complete investors history, request access »